new glp 1 receptor agonists A Closer Look at the Dermatological Profile of GLP-1 GLP-1 Receptor Agonists as Treatments

Results The first cohort included 36082 GLP-1 receptor agonist users (median follow-up 1.3 years) and 234028 DPP-4 inhibitor users (median follow-up 1.7 years)

The Revolutionary Role of GLP-1 Agonists and SGLT-2 Inhibitors in Managing Diabetes and Chronic Kidney Disease Shankar Chakkera, Elizabeth J

This guide examines peer-reviewed research on EVOO and GLP-1 secretion, hydroxytyrosol and insulin sensitivity, oleocanthal and inflammation, and why these olive-specific compounds are distinct from other dietary polyphenols

Ultrasound assessments could improve risk stratification for perioperative management

In a phase 2 study, amycretin showed a mean weight reduction of up to 24.3%, which is comparable to or even greater than the weight loss seen with tirzepatide and similar to the results for retatrutide

These findings align with prior randomized trials and meta-analyses suggesting class-level cardiovascular benefit